How big pharma is quietly reprogramming our children.

The American Academy of Pediatrics lit the fuse in 2023. Their recommendation to use GLP-1 weight-loss drugs in children and adolescents wasn’t just a nod to pharmaceutical innovation — it was a signal flare to industry, a green light to experiment on the developing brain. And experiment they did. A review of more than 310,000 patient records reveals the consequences: a 65 percent surge in prescriptions. Some might call this progress. They’re wrong. This is mass chemical intervention dressed up in a lab coat.

Before the guidelines, semaglutide — a compound found in drugs like Ozempic and Wegovy — was prescribed to just 2.5 percent of young patients. Afterward? Nearly 27 percent. That’s a tenfold leap. Not a cautious rollout. A gold rush. Pediatricians, parents, and policymakers have quietly signed off on the neurological reprogramming of an entire generation. And the worst part is that no one really knows what’s coming next. …

Continue reading >>>>>>>>>>